 | | | Vol. 12.20 – 4 June, 2021 |
|
|
|
| Scientists applied fluorescence in vivo flow cytometry to monitor circulating tumor cells noninvasively in an orthotopic mouse model of human prostate cancer.
[Light-Science & Applications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that the molecular chaperone GRP75 was a key player in prostate cancer cells by maintaining the protein stability of SIX1, a transcription factor for embryonic development.
[Oncogene] |
|
|
|
| Researchers found that depletion of either FKBP51 or FKBP52 reduced androgen receptor (AR) dimer formation, chromatin binding and phosphorylation, suggesting defective AR signaling.
[Molecular Oncology] |
|
|
|
| The authors designed a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma patients, to identify hypoxia in prostate cancer.
[Cancers] |
|
|
|
| Researchers investigated the role of small leucine zipper protein in matrix metalloproteinase-13 expression and its involvement in CRPC metastasis.
[Carcinogenesis] |
|
|
|
| Investigators evaluated the inhibitory effects of resveratrol on cell proliferation associated with prostatic hyperplasia (PBH) using WPMY-1 cells.
[International Journal of Molecular Sciences] |
|
|
|
| The authors utilized the established non-malignant HPr1-AR prostate epithelial cell model that upon androgen exposure committed to a luminal cell differentiation trajectory from that of a basal-like state.
[Scientific Reports] |
|
|
|
| Treatment of C4-2 cells with the 4F2 cell-surface antigen heavy chain was found to suppress cellular growth, migratory and invasive abilities, with this effect occurring through the cell cycle, with a significant decrease in S phase and a significant increase in G0/G1 phase, suggesting cell cycle arrest.
[Scientific Reports] |
|
|
|
| Scientists found that chronic exposure to antimony promoted cell growth and lipid metabolic disequilibrium in prostate cancer.
[Toxicology Letters] |
|
|
|
| Anti-cancer activity of catechin nanoemulsions prepared from Oolong tea leaf waste was studied on prostate cancer cells DU-145 and DU-145-induced tumors in mice.
[Molecules] |
|
|
|
|
| A great deal of evidence suggests that significant progress has been made in the prostate-specific membrane antigen (PSMA)-targeted therapy of prostate cancer (PCa). The authors review different PSMA-targeted therapies for PCa.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| SOFIE announced that they will be commercially manufacturing and distributing PYLARIFY® injection, an F 18-labeled prostate-specific membrane antigen targeted positron emission tomography imaging agent.
[SOFIE] |
|
|
|
| Lantheus Holdings, Inc. announced that the FDA has approved PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer.
[Lantheus Holdings, Inc.] |
|
|
|
|
|
|
|
| | Bayer – Basel, Switzerland |
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | H. Lee Moffitt Cancer Center – Tampa, Florida, United States |
|
|
|
| | The University of Edinburgh – Edinburgh, Scotland, United Kingdom |
|
|
|
| | Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
